⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockIsraelNasdaqGS

INMD

InMode Ltd.

Healthcare · Medical Devices

14.79USD

-0.0200 (-0.14%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.32▼$0.3403
Next quarter$0.38▼$0.4104
Current year$1.3▼$1.3213
Next year$1.37▼$1.4804

Recent quarters

Beat in 3 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.33$0.35+0.02 (+5.4%)
2026-03-31$0.3$0.25-0.05 (-16.1%)
2025-12-31$0.42$0.46+0.04 (+10.4%)
2025-09-30$0.35$0.38+0.03 (+7.0%)

Wall Street coverage

80 ratings from 10 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
BarclaysMaintainedOverweight$21 $19May 7, 2026
BairdMaintainedNeutral$17 $14May 7, 2026
Canaccord GenuityMaintainedHold$16 $15Dec 17, 2025
UBSMaintainedNeutral$16.25 $16Nov 6, 2025
Canaccord GenuityMaintainedHold$14 $16Oct 10, 2025
NeedhamReiteratedHold—Oct 10, 2025
NeedhamReiteratedHold—Jul 30, 2025
BarclaysMaintainedOverweight$24 $21Jul 30, 2025
Canaccord GenuityMaintainedHold$15Jul 11, 2025
BarclaysMaintainedOverweight$29 $24Apr 30, 2025
UBSMaintainedNeutral$19 $16.25Apr 29, 2025
BTIGDowngraded from BuyNeutral—Apr 29, 2025
Canaccord GenuityMaintainedHold$17 $15Apr 29, 2025
NeedhamReiteratedHold—Apr 28, 2025
JefferiesMaintainedHold$16 $15Apr 14, 2025
NeedhamReiteratedHold—Apr 14, 2025
NeedhamReiteratedHold—Apr 9, 2025
BarclaysMaintainedOverweight$26 $29Feb 5, 2025
NeedhamMaintainedHold—Feb 4, 2025
BarclaysMaintainedOverweight$27 $26Jan 9, 2025
NeedhamReiteratedHold—Oct 31, 2024
Alliance Global PartnersInitiatedBuy$20Oct 21, 2024
BTIGInitiatedBuy$25Oct 17, 2024
BarclaysMaintainedOverweight$29 $27Oct 14, 2024
NeedhamReiteratedHold—Oct 10, 2024

Insider transactions

4 filings from 4 insiders · 0 buy / 0 sell over 6m

Officers and directors of INMD, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
ITZKOVICH MOSHEChief Financial OfficerGrant14.0k——Aug 4, 2026
NASS SHLOMODirectorGrant2.0k——Jul 30, 2026
KENNETH NADAVDirectorGrant2.0k——Jul 30, 2026
RON HADARDirectorGrant2.0k——Jul 30, 2026

Analyst Notes

Sign in to write

No analyst notes on INMD yet.

Analyst Ratings

3 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current00500Hold3.00
1 mo ago00500Hold3.00
2 mo ago00500Hold3.00
Price target$16.17$15.00 – $17.00
+9.3% to target